S&P 500   4,967.75 (-0.16%)
DOW   38,518.84 (-0.12%)
QQQ   424.08 (-0.76%)
AAPL   182.47 (+0.50%)
MSFT   398.70 (-1.02%)
META   464.59 (-1.41%)
GOOGL   141.03 (-0.06%)
AMZN   169.62 (+1.52%)
TSLA   197.34 (+1.85%)
NVDA   681.44 (-1.88%)
NIO   6.13 (+2.85%)
AMD   163.96 (-1.04%)
BABA   75.91 (+3.79%)
T   16.89 (-0.12%)
F   12.26 (+0.08%)
MU   80.25 (-0.57%)
CGC   3.45 (-2.54%)
GE   148.59 (-0.02%)
DIS   108.69 (-0.69%)
AMC   4.74 (+1.72%)
PFE   27.55 (-0.14%)
PYPL   58.12 (-0.87%)
XOM   103.90 (+1.12%)
S&P 500   4,967.75 (-0.16%)
DOW   38,518.84 (-0.12%)
QQQ   424.08 (-0.76%)
AAPL   182.47 (+0.50%)
MSFT   398.70 (-1.02%)
META   464.59 (-1.41%)
GOOGL   141.03 (-0.06%)
AMZN   169.62 (+1.52%)
TSLA   197.34 (+1.85%)
NVDA   681.44 (-1.88%)
NIO   6.13 (+2.85%)
AMD   163.96 (-1.04%)
BABA   75.91 (+3.79%)
T   16.89 (-0.12%)
F   12.26 (+0.08%)
MU   80.25 (-0.57%)
CGC   3.45 (-2.54%)
GE   148.59 (-0.02%)
DIS   108.69 (-0.69%)
AMC   4.74 (+1.72%)
PFE   27.55 (-0.14%)
PYPL   58.12 (-0.87%)
XOM   103.90 (+1.12%)
S&P 500   4,967.75 (-0.16%)
DOW   38,518.84 (-0.12%)
QQQ   424.08 (-0.76%)
AAPL   182.47 (+0.50%)
MSFT   398.70 (-1.02%)
META   464.59 (-1.41%)
GOOGL   141.03 (-0.06%)
AMZN   169.62 (+1.52%)
TSLA   197.34 (+1.85%)
NVDA   681.44 (-1.88%)
NIO   6.13 (+2.85%)
AMD   163.96 (-1.04%)
BABA   75.91 (+3.79%)
T   16.89 (-0.12%)
F   12.26 (+0.08%)
MU   80.25 (-0.57%)
CGC   3.45 (-2.54%)
GE   148.59 (-0.02%)
DIS   108.69 (-0.69%)
AMC   4.74 (+1.72%)
PFE   27.55 (-0.14%)
PYPL   58.12 (-0.87%)
XOM   103.90 (+1.12%)
S&P 500   4,967.75 (-0.16%)
DOW   38,518.84 (-0.12%)
QQQ   424.08 (-0.76%)
AAPL   182.47 (+0.50%)
MSFT   398.70 (-1.02%)
META   464.59 (-1.41%)
GOOGL   141.03 (-0.06%)
AMZN   169.62 (+1.52%)
TSLA   197.34 (+1.85%)
NVDA   681.44 (-1.88%)
NIO   6.13 (+2.85%)
AMD   163.96 (-1.04%)
BABA   75.91 (+3.79%)
T   16.89 (-0.12%)
F   12.26 (+0.08%)
MU   80.25 (-0.57%)
CGC   3.45 (-2.54%)
GE   148.59 (-0.02%)
DIS   108.69 (-0.69%)
AMC   4.74 (+1.72%)
PFE   27.55 (-0.14%)
PYPL   58.12 (-0.87%)
XOM   103.90 (+1.12%)

Celadon Pharmaceuticals (CEL) Stock Forecast & Price Target

GBX 115
+2.50 (+2.22%)
(As of 01:11 PM ET)

Celadon Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

GBX 222.50
High ForecastGBX 235
Average ForecastGBX 222.50
Low ForecastGBX 210
TypeCurrent Forecast
2/21/23 to 2/21/24
1 Month Ago
1/22/23 to 1/22/24
3 Months Ago
11/23/22 to 11/23/23
1 Year Ago
2/21/22 to 2/21/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 222.50GBX 222.50GBX 222.50GBX 210
Get Celadon Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter.


CEL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Celadon Pharmaceuticals Stock vs. The Competition

TypeCeladon PharmaceuticalsMedical Companies
Consensus Rating Score
3.00
2.67
Consensus RatingBuyModerate Buy
News Sentiment RatingNeutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/29/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSpeculative BuyGBX 210 ➝ GBX 235+89.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:18 AM ET.












CEL Price Target - Frequently Asked Questions

What is Celadon Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Celadon Pharmaceuticals stock is Buy based on the current 2 buy ratings for CEL. The average twelve-month price prediction for Celadon Pharmaceuticals is GBX 222.50 with a high price target of GBX 235 and a low price target of GBX 210. Learn more on CEL's analyst rating history.

Do Wall Street analysts like Celadon Pharmaceuticals more than its competitors?

Analysts like Celadon Pharmaceuticals more than other Medical companies. The consensus rating for Celadon Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how CEL compares to other companies.

Does Celadon Pharmaceuticals's stock price have much upside?

According to analysts, Celadon Pharmaceuticals's stock has a predicted upside of 59.50% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (LON:CEL) was last updated on 2/21/2024 by MarketBeat.com Staff